- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03820362
The Role of Personal Identity in Psychotic Symptoms: a Study With the Repertory Grid Technique
Personal Identity, Cognitive Factors and Psychotic Symptoms in Schizophrenia and Related Disorders: A Cross-sectional Study With the Repertory Grid Technique
Study Overview
Status
Conditions
Detailed Description
Over recent years, the importance of the sense of self and personal identity in psychopathology and its treatment has been highlighted. Several studies inspired in the Personal Construct Psychology framework have found a variety of identity characteristics in clinical conditions such as depression or eating disorders, but the evidence in schizophrenia and other psychotic related disorders is scarce.
In addition, current psychological models of positive and negative symptoms highlight the influence of neurocognition, social cognition and self-concepts in the development and maintenance of psychotic experiences. Despite the recognized need of person-centered approaches to understand psychopathology processes in psychosis, psychological models for explaining psychotic symptoms have not explored sufficiently the role of this kind of person-centered measures.
Aim
1. To examine the influence of the structure of personal identity and other relevant cognitive factors in positive and negative symptoms
Hypotheses
- Positive symptoms will be influenced by dichotomous thinking style and construction of self as measured with the RGT.
- Negative symptoms will be affected by the richness of the construct system as measured with the RGT.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Barcelona
-
Sant Boi De Llobregat, Barcelona, Spain
- Parc Sanitary Sant Joan de Déu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- diagnosis of schizophrenia, psychotic disorder not otherwise specified, delusional disorder, schizoaffective disorder, brief psychotic disorder, or schizophreniform disorder
- age between 18 and 60 years.
- patients from outpatient mental health units
Exclusion Criteria:
- traumatic brain injury, dementia, or intellectual disability (pre-morbid IQ <70)
- current substance dependence
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-ideal discrepancy, RGT
Time Frame: 2 hours
|
Self-esteem.
Possible range: 0-0,60.
Higher values represent a worse outcome
|
2 hours
|
Self-others discrepancy, RGT
Time Frame: 2 hours
|
Perceived social isolation.
Possible range: 0-0,60.
Higher values represent a worse outcome
|
2 hours
|
Interpersonal construct differentiation, RGT
Time Frame: 2 hours
|
Percentage of Variance Accounted for the First Factor.
Possible range: 0-100.
Higher values represent a worse outcome
|
2 hours
|
Polarization, RGT
Time Frame: 2 hours
|
Dichotomous thinking style in the interpersonal context.
Possible range: 0-100.
Higher values represent a worse outcome
|
2 hours
|
Number of elicited constructs, RGT
Time Frame: 2 hours
|
Quantity of constructs that the person is able to express to describe self and others.
Possible range: 10-50.
Higher values represent a better outcome
|
2 hours
|
Psychotic symptoms (PANSS, Kay et al. 1987; Peralta & Cuesta, 1994).
Time Frame: 40 minutes
|
Positive and negative symptoms of psychosis.
Range: 7-112.
Higher values represent a worse outcome.
|
40 minutes
|
Metacognition: BCIS (Beck et al. 2004; Gutiérrez-Zotes et al. 2012); Garety et al, 1991; Dudley et al, 1997)
Time Frame: 15 minutes
|
Cognitive insight.
Range: 0-45.
Higher values represent a better outcome
|
15 minutes
|
Theory of mind: the Hinting Task (Corcoran et al., 1995; Gil-Sanz et al., 2012)
Time Frame: 5 minutes
|
Possible range: 0-12.
Higher values represent a better outcome
|
5 minutes
|
General intellectual functioning (WAIS)
Time Frame: 20 minutes
|
vocabulary subscale.
Range: 70-140.
Higher values represent a better outcome
|
20 minutes
|
Executive functioning: WSCT (Bergs et al., 1948)
Time Frame: 15 minutes
|
Wisconsin Card Sorting Test.
Categories completed and perseverative errors.
Higher values represent a better outcome
|
15 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sociodemographical data
Time Frame: 10 minutes
|
Gender, chronicity, antipsychotic dosage, diagnosis, age, marital status, education level, employment situation
|
10 minutes
|
Depressive symptoms
Time Frame: 10 minutes
|
Beck Depression Inventory (Beck et al. 1996; Sanz, Perdigón & Vázquez, 2003).
Range_ 0-63.
High values represent a worse outcome.
|
10 minutes
|
General functioning
Time Frame: 5 minutes
|
Global Assessment of Functioning (Endicot et al., 1976).
Range: 0-100.
Higher values represent a better outcome.
|
5 minutes
|
Self-esteem
Time Frame: 5 minutes
|
Rosenberg self-esteem scale (Martín Albó et al., 2007).
Range: 0-40.
Higher values represent a better outcome
|
5 minutes
|
Social functioning
Time Frame: 20 minutes
|
Social Functioning Scale (Birchwood et al., 1990; Torres & Olivares, 2000).
Range: Range: 45-195
|
20 minutes
|
Psychological distress
Time Frame: 10 minutes
|
CORE-OM (Evans et al., 2002; Trujillo et al., 2016).
Range: 0-4.
Higher values represent a worse outcome
|
10 minutes
|
Jumping to Conclusions
Time Frame: 15 minutes
|
The beads task (Garety et al., 1991; Dudley et al, 1997).
Dichotomous: yes/no.
A "yes" represents a worse outcome
|
15 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Helena García-Mieres, MsC, Universitat de Barcelona & Parc Sanitari Sant Joan de Déu
- Study Director: Susana Ochoa, PhD, Parc Sanitari Sant Joan de Déu
- Study Director: Guillem Feixas, PhD, University of Barcelona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FPU15/01721
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychotic Disorders
-
Medical College of WisconsinCompletedSchizophrenia | Affective Disorders | Psychotic Disorder | Psychotic Mood Disorder
-
Søren Dinesen ØstergaardCompletedAffective Disorders, PsychoticDenmark
-
VA Office of Research and DevelopmentNot yet recruitingMI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMIHomelessness | Schizophrenia Spectrum Disorders | Psychotic Mood Disorders | Psychotic Affective Disorders | Ill-Housed PersonsUnited States
-
Instituto de Investigación Hospital Universitario...CompletedSchizophrenia and Disorders With Psychotic Feature | Psychotic EpisodeSpain
-
University Hospital, CaenRecruiting
-
Instituto de Investigación Hospital Universitario...Carlos III Health Institute; European Regional Development FundCompletedSchizophrenia and Disorders With Psychotic Features | Psychotic EpisodeSpain
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
University of MinnesotaUniversity of California, San FranciscoCompletedPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Cognitive Impairment | Psychosis | Treatment | Psychotic Depression | Psychotic Episode | Active Control | Psychotic Mood DisordersUnited States
-
University of California, San DiegoActive, not recruitingSchizophrenia | Schizoaffective Disorder | Mood Disorder, PsychoticUnited States
-
Boston Medical CenterNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterCompletedPsychotic Disorders | Psychosis | Psychotic EpisodeUnited States